Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Sacred Heart Medical Center, Spokane, Washington, United States
University of New Mexico Hospital, Albuquerque, New Mexico, United States
The Zucker Hillside Hospital, Glen Oaks, New York, United States
UC Davis Health, Sacramento, California, United States
OSF Saint Francis Medical Center, Peoria, Illinois, United States
University of Michigan, Ann Arbor, Michigan, United States
Pfizer Local Country office, Tokyo, Shibuya-ku, Japan
Department of Psychiatry, University of Bonn, Bonn, Germany
UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.